Efficacy of 4-Haptic Bitoric Intraocular Lens Implantation in Asian Patients with Cataract and Astigmatism
Overview
Authors
Affiliations
Purpose: To determine the efficacy of 4-haptic bitoric intraocular lens (IOL) implantation in Asian patients with cataract and astigmatism.
Methods: A total of 19 eyes with ≤25.0 mm axial length and ≥0.75 diopters (D) corneal astigmatism were included in this prospective non-comparative study. All subjects underwent phacoemulsification with implantation of an AT Torbi 709M IOL. Visual and refractive outcomes as well as toric IOL axis were evaluated during a 3-month follow-up. Errors in predicted residual spherical equivalent were calculated by subtracting predicted residual spherical equivalent from postoperative refraction.
Results: Uncorrected and corrected distance visual acuity improved significantly 3 months after surgery, from 0.43 to 0.05 and from 0.24 to -0.05, respectively. Mean refractive cylinders also decreased significantly, from -1.91 preoperatively to -0.54 D 3 months after surgery. Mean J0 and J45 decreased 3 months postoperatively, from 0.26 to 0.03 D and from 0.24 to -0.06 D, respectively. After 3 months, mean absolute IOL rotation was 1.81°. Errors in predicted residual spherical equivalent showed a hyperopic shift of 0.35 D.
Conclusions: Implantation of 4-haptic bitoric IOL proved to be effective for correcting astigmatism in Asian eyes during cataract surgery.
Kim S, Son Y, Hyon J Korean J Ophthalmol. 2025; 39(1):64-70.
PMID: 39780041 PMC: 11856048. DOI: 10.3341/kjo.2024.0117.
Sun H, Wang C, Wu H Eye Vis (Lond). 2024; 11(1):49.
PMID: 39736769 PMC: 11684149. DOI: 10.1186/s40662-024-00414-0.
Toric intraocular lens: A literature review.
Thulasidas M, Kadam A Taiwan J Ophthalmol. 2024; 14(2):197-208.
PMID: 39027059 PMC: 11254006. DOI: 10.4103/tjo.tjo_43_21.
Tana-Rivero P, Munoz-Tomas J, Orts-Vila P, Artiaga-Elordi E, Pastor-Pascual F, Marin-Sanchez J Clin Ophthalmol. 2024; 18:1933-1944.
PMID: 38983598 PMC: 11231029. DOI: 10.2147/OPTH.S467523.
Sun J, Bai H, Cui W, Wu X Graefes Arch Clin Exp Ophthalmol. 2023; 262(3):847-855.
PMID: 37672101 DOI: 10.1007/s00417-023-06232-9.